Quarterly report pursuant to Section 13 or 15(d)

Condensed Combined and Consolidated Statements of Stockholders' Equity (Unaudited)

v3.19.3.a.u2
Condensed Combined and Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Series A Preferred Stock [Member]
Roivant Sciences Ltd. (RSL) [Member]
Common Stock [Member]
Common Stock Subscribed
Additional Paid-In- Capital
Additional Paid-In- Capital
Roivant Sciences Ltd. (RSL) [Member]
Net Parent Investment
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning Balance at Mar. 31, 2018 $ (1,497)         $ (1,658) $ 161  
Beginning Balance,Shares at Mar. 31, 2018                  
Net transfers from parent 5,419           5,419    
Foreign currency translation adjustment 35               35  
Net loss (4,368)             (4,368)    
Ending Balance at Jun. 30, 2018 (411)         (607) 196  
Ending Balance,Shares at Jun. 30, 2018       0            
Beginning Balance at Mar. 31, 2018 (1,497)         (1,658) 161  
Beginning Balance,Shares at Mar. 31, 2018                  
Net loss (19,567)                  
Ending Balance at Dec. 31, 2018 7,962     $ 4 (3) $ 23,527     240 $ (15,806)
Ending Balance,Shares at Dec. 31, 2018       37,953,576            
Beginning Balance at Jun. 30, 2018 (411)         (607) 196  
Beginning Balance,Shares at Jun. 30, 2018       0            
Common share subscription, shares       4,890,662            
Ending Balance at Jul. 06, 2018 (411)     $ 0 0     (607) 196  
Ending Balance,Shares at Jul. 06, 2018       4,890,662            
Common share subscription       $ 3 (3)          
Common share subscription, shares       31,789,305            
Transfer to Accumulated Deficit               $ 607   (607)
Cash contribution 7,021         7,021        
Capital contribution - stock-based compensation 481         481        
Capital contribution - expenses allocated from Roivant Sciences Ltd.     $ 1,472       $ 1,472      
Stock-based compensation 1         1        
Foreign currency translation adjustment 106               106  
Net loss (6,350)                 (6,350)
Ending Balance at Sep. 30, 2018 2,320     $ 3 (3) 8,975     302 (6,957)
Ending Balance,Shares at Sep. 30, 2018       36,679,967            
Issuance of common shares, net 9,768     $ 1   9,767        
Issuance of common shares, net, shares       1,273,609            
Cash contribution 3,973         3,973        
Capital contribution - stock-based compensation 225         225        
Capital contribution - expenses allocated from Roivant Sciences Ltd.     575       575      
Stock-based compensation 12         12        
Foreign currency translation adjustment (62)               (62)  
Net loss (8,849)                 (8,849)
Ending Balance at Dec. 31, 2018 7,962     $ 4 (3) 23,527     240 (15,806)
Ending Balance,Shares at Dec. 31, 2018       37,953,576            
Beginning Balance at Mar. 31, 2019 7,339 [1]     $ 4 (3) 31,830     346 (24,838)
Beginning Balance,Shares at Mar. 31, 2019       38,590,381            
Capital contribution - stock-based compensation 35         35        
Capital contribution - expenses allocated from Roivant Sciences Ltd.     331       331      
Stock-based compensation 537         537        
Foreign currency translation adjustment (291)               (291)  
Net loss (20,059)                 (20,059)
Ending Balance at Jun. 30, 2019 (12,108)     $ 4 (3) 32,733     55 (44,897)
Ending Balance,Shares at Jun. 30, 2019       38,590,381            
Beginning Balance at Mar. 31, 2019 7,339 [1]     $ 4 (3) 31,830     346 (24,838)
Beginning Balance,Shares at Mar. 31, 2019       38,590,381            
Net loss (45,837)                  
Ending Balance at Dec. 31, 2019 111,862 [1]     $ 5   182,679     (147) (70,675)
Ending Balance,Shares at Dec. 31, 2019   10,000   54,655,376            
Beginning Balance at Jun. 30, 2019 (12,108)     $ 4 (3) 32,733     55 (44,897)
Beginning Balance,Shares at Jun. 30, 2019       38,590,381            
Settlement of common share subscription 1       $ 3 (2)        
Capital contribution - stock-based compensation 18         18        
Capital contribution - expenses allocated from Roivant Sciences Ltd.     220       220      
Stock-based compensation 3,119         3,119        
Foreign currency translation adjustment (54)               (54)  
Net loss (14,482)                 (14,482)
Ending Balance at Sep. 30, 2019 (23,286)     $ 4   36,088     1 (59,379)
Ending Balance,Shares at Sep. 30, 2019       38,590,381            
Conversion of convertible promissory notes 35,587         35,587        
Conversion of convertible promissory notes, shares       3,499,995            
Issuance of preferred and common stock, net of deferred offering costs upon Business Combination & Recapitalization 109,276 $ 0   $ 1   109,275        
Issuance of preferred and common stock, net of deferred offering costs upon Business Combination & Recapitalization, shares   10,000   12,565,000            
Capital contribution - stock-based compensation 82         82        
Capital contribution - expenses allocated from Roivant Sciences Ltd.     $ 315       $ 315      
Stock-based compensation 1,332         1,332        
Foreign currency translation adjustment (148)               (148)  
Net loss (11,296)                 (11,296)
Ending Balance at Dec. 31, 2019 $ 111,862 [1]     $ 5   $ 182,679     $ (147) $ (70,675)
Ending Balance,Shares at Dec. 31, 2019   10,000   54,655,376            
[1] Retroactively restated for the reverse recapitalization as described in Note 1.